Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Humacyte (NASDAQ:HUMA) and maintained a price target of $16.
August 15, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Humacyte and maintained a price target of $16.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $16 price target indicates a positive outlook for Humacyte. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100